We are studying the effects of amivantamab in patients with recurrent or metastatic head and neck squamous cell carcinoma. This trial looks at its use alone and with other standard treatments to see how well it works.
We are testing a new type of CAR T cell therapy for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia. The study aims to evaluate the safety and appropriate dosage of this treatment.
We are investigating a new treatment called OKI-219 for patients with breast cancer. This study looks at how it works alone and with other therapies to improve outcomes.
We are comparing how well healthy volunteers tolerate two oral medications for gastrointestinal side effects. This study aims to understand which option may be easier on the stomach.
We are investigating the safety and effects of new antibodies for people with hepatitis B. This study aims to learn more about how these treatments may help manage the disease.
We are studying a new treatment for patients with advanced solid tumors to see how well it works compared to current options. This research aims to improve outcomes for those affected by these cancers.
We are testing a new treatment combining chemotherapy and a MEK inhibitor for patients with metastatic non-squamous non-small cell lung adenocarcinoma. The goal is to see if this approach is safe and effective for those with low PD-L1 levels.
We are studying how different tablet forms of milvexian are absorbed in healthy adults and how food affects this process. We also want to know if participants find these formulations acceptable.
We are testing the safety and tolerability of D3S-001, alone or with other cancer medicines, for adults with advanced solid tumors that have a KRAS p.G12C mutation. This study aims to understand how the treatment works and its effects on tumors.
We are testing a new medication, COR-1167, to see how safe it is and how the body processes it in people with chronic heart failure and healthy volunteers. This study aims to gather important information about its effects.
We are evaluating a new DNA vaccine to see if it is safe and can help the body fight against Crimean Congo Hemorrhagic Fever. This study is for healthy volunteers who want to contribute to vaccine research.
We are testing a personalized gene therapy for patients with advanced head and neck cancer. The goal is to see if it can improve treatment outcomes compared to standard options.
We are investigating whether AZD0305, alone or with other cancer therapies, is safe and effective for adults with relapsed or refractory multiple myeloma.
We are investigating whether taking ibrutinib intermittently can improve outcomes for people with chronic lymphocytic leukemia. This study aims to find out if this approach is effective compared to continuous treatment.
We are testing a new treatment called PM54 for patients with advanced solid tumors. The goal is to evaluate its safety and how well it works compared to existing options.
We are assessing whether JJP-1212 is safe and can effectively stimulate an immune response in humans. This study aims to understand its tolerability and potential benefits.
We are investigating the effects of Lu AG22515 on eye bulging in adults with moderate-to-severe Thyroid Eye Disease. This study aims to see if it can improve symptoms related to this condition.
We are evaluating the safety and tolerability of a new drug, DNL593, in healthy individuals and those with frontotemporal dementia. This study aims to understand how the drug works in the body and its effects over time.
We are testing the safety and effectiveness of MK-2870, alone or with other cancer treatments, for people with gastrointestinal cancers. This study aims to see how well it works in reducing tumors and improving patient outcomes.
We are exploring a new combination of chemotherapy and immunotherapy for patients with borderline resectable pancreatic cancer. The goal is to see if this treatment improves survival and surgical outcomes.